Requirements for designing organ-on-a-chip platforms to model the pathogenesis of liver disease

Ishida, Susumu

doi:10.1016/b978-0-12-817202-5.00005-x

Cited by 3 publications

(3 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, HepaRG cells are known for lower metabolic activity, which can be enhanced by adding 2% dimethyl sulfoxide. However, in a co-culture, this can result in the proliferation of non-parenchymal hepatic cells [ 91 ]. The way to facilitate cellular proliferation was suggested by Zuo et al, who generated HepatoCells from primary human hepatocytes, which allowed higher reproducibility by knocking out specific genes [ 92 ].…”

Section: Challenges In Designing Liver Disease-on-chip Modelsmentioning

confidence: 99%

“…Within the liver, the inflow to the sinusoid comes from arterial blood (rich in oxygen) and portal vein (rich in nutrients) and goes towards the central vein. This facilitates the metabolism of drugs/chemicals to be biotransformed and maintains the oxygen delivery even to less oxygenated zones, which is essential for the expression of some genes [ 91 ]. Earlier, it was suggested to decrease the seeding density of cells in vitro to allow the media to accommodate greater amounts of oxygen [ 99 ].…”

Section: Challenges In Designing Liver Disease-on-chip Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Microfluidic Organ-on-a-Chip Devices for Liver Disease Modeling In Vitro

2022

View full text Add to dashboard Cite

Mortality from liver disease conditions continues to be very high. As liver diseases manifest and progress silently, prompt measures after diagnosis are essential in the treatment of these conditions. Microfluidic organs-on-chip platforms have significant potential for the study of the pathophysiology of liver diseases in vitro. Different liver-on-a-chip microphysiological platforms have been reported to study cell-signaling pathways such as those activating stellate cells within liver diseases. Moreover, the drug efficacy for liver conditions might be evaluated on a cellular metabolic level. Here, we present a comprehensive review of microphysiological platforms used for modelling liver diseases. First, we briefly introduce the concept and importance of organs-on-a-chip in studying liver diseases in vitro, reflecting on existing reviews of healthy liver-on-a-chip platforms. Second, the techniques of cell cultures used in the microfluidic devices, including 2D, 3D, and spheroid cells, are explained. Next, the types of liver diseases (NAFLD, ALD, hepatitis infections, and drug injury) on-chip are explained for a further comprehensive overview of the design and methods of developing liver diseases in vitro. Finally, some challenges in design and existing solutions to them are reviewed

show abstract

Section: Challenges In Designing Liver Disease-on-chip Modelsmentioning

confidence: 99%

Section: Challenges In Designing Liver Disease-on-chip Modelsmentioning

confidence: 99%

Microfluidic Organ-on-a-Chip Devices for Liver Disease Modeling In Vitro

2022

View full text Add to dashboard Cite

show abstract

“…One is cell criteria, and the other is the standard for material and equipment. 74 The considerations of these two aspects together will enhance the MPS performance standards.…”

Section: Hairuo Wen Phd National Institutes For Food and Drug Control Chinamentioning

confidence: 99%

Emerging technologies and their impact on regulatory science

Anklam

Bahl

Ball

et al. 2021

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

There is an evolution and increasing need for the utilization of emerging cellular, molecular and in silico technologies and novel approaches for safety assessment of food, drugs, and personal care products. Convergence of these emerging technologies is also enabling rapid advances and approaches that may impact regulatory decisions and approvals. Although the development of emerging technologies may allow rapid advances in regulatory decision making, there is concern that these new technologies have not been thoroughly evaluated to determine if they are ready for regulatory application, singularly or in combinations. The magnitude of these combined technical advances may outpace the ability to assess fit for purpose and to allow routine application of these new methods for regulatory purposes. There is a need to develop strategies to evaluate the new technologies to determine which ones are ready for regulatory use. The opportunity to apply these potentially faster, more accurate, and cost-effective approaches remains an important goal to facilitate their incorporation into regulatory use. However, without a clear strategy to evaluate emerging technologies rapidly and appropriately, the value of these efforts may go unrecognized or may take longer. It is important for the regulatory science field to keep up with the research in these technically advanced areas and to understand the science behind these new approaches. The regulatory field must understand the critical quality attributes of these novel approaches and learn from each other's experience so that workforces can be trained to prepare for emerging global regulatory challenges. Moreover, it is essential that the regulatory community must work with the technology developers to harness collective capabilities towards developing a strategy for evaluation of these new and novel assessment tools.

show abstract

Implementing organ-on-chip in a next-generation risk assessment of chemicals: a review

et al. 2022

View full text Add to dashboard Cite

Organ-on-chip (OoC) technology is full of engineering and biological challenges, but it has the potential to revolutionize the Next-Generation Risk Assessment of novel ingredients for consumer products and chemicals. A successful incorporation of OoC technology into the Next-Generation Risk Assessment toolbox depends on the robustness of the microfluidic devices and the organ tissue models used. Recent advances in standardized device manufacturing, organ tissue cultivation and growth protocols offer the ability to bridge the gaps towards the implementation of organ-on-chip technology. Next-Generation Risk Assessment is an exposure-led and hypothesis-driven tiered approach to risk assessment using detailed human exposure information and the application of appropriate new (non-animal) toxicological testing approaches. Organ-on-chip presents a promising in vitro approach by combining human cell culturing with dynamic microfluidics to improve physiological emulation. Here, we critically review commercial organ-on-chip devices, as well as recent tissue culture model studies of the skin, intestinal barrier and liver as the main metabolic organ to be used on-chip for Next-Generation Risk Assessment. Finally, microfluidically linked tissue combinations such as skin–liver and intestine–liver in organ-on-chip devices are reviewed as they form a relevant aspect for advancing toxicokinetic and toxicodynamic studies. We point to recent achievements and challenges to overcome, to advance non-animal, human-relevant safety studies.

show abstract

Requirements for designing organ-on-a-chip platforms to model the pathogenesis of liver disease

Cited by 3 publications

References 150 publications

Microfluidic Organ-on-a-Chip Devices for Liver Disease Modeling In Vitro

Microfluidic Organ-on-a-Chip Devices for Liver Disease Modeling In Vitro

Emerging technologies and their impact on regulatory science

Implementing organ-on-chip in a next-generation risk assessment of chemicals: a review

Contact Info

Product

Resources

About